Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

2014779 citationsJournal Articlebronze Open Access

Authors

Antonio Palumbo · Ospedale Sant'Anna

Federica Cavallo · University of Turin

Francesca Gay · University of Turin

Francesco Di Raimondo · University of Catania

Dina Ben Yehuda · Hadassah Academic College

Maria Teresa Petrucci · Sapienza University of Rome

Sara Pezzatti ·

Abstract

Consolidation therapy with high-dose melphalan plus stem-cell transplantation, as compared with MPR, significantly prolonged progression-free and overall survival among patients with multiple myeloma who were 65 years of age or younger. Lenalidomide maintenance, as compared with no maintenance, significantly prolonged progression-free survival. (Funded by Celgene; ClinicalTrials.gov number, NCT00551928.).

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Ubiquitin and proteasome pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 10, pp. 895-905

DOI: 10.1056/nejmoa1402888

Field-Weighted Citation Impact: 48.97